Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PATRICIA S BRALY

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1457316283
CMS profile
202472
Location
COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$57,423.65

100 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PATRICIA S BRALY

NPI 1457316283 · CMS profile ID 202472

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457316283?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PATRICIA S BRALY, NPI 1457316283, CMS profile ID 202472. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457316283?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PATRICIA S BRALY, NPI 1457316283, CMS profile ID 202472. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457316283?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PATRICIA S BRALY, NPI 1457316283, CMS profile ID 202472, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–100 of 100 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1457316283?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

100 matching records · $57,423.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 100 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 100.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
TESARO, Inc. $36.2505/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555709 CMS
TESARO, Inc. $36.3705/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555711 CMS
TESARO, Inc. $45.4505/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555713 CMS
TESARO, Inc. $119.3305/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555715 CMS
TESARO, Inc. $12.0504/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555707 CMS
Otsuka America Pharmaceutical, Inc. $99.6704/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687357725 CMS
TherapeuticsMD, Inc. $15.8504/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703043525 CMS
Clovis Oncology, Inc. $15.7904/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688687335 CMS
Merck Sharp & Dohme Corporation $17.3604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695412639 CMS
AstraZeneca Pharmaceuticals LP $5,500.0004/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685562565 CMS
TESARO, Inc. $21.5403/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555705 CMS
AstraZeneca Pharmaceuticals LP $4,100.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685595313 CMS
AstraZeneca Pharmaceuticals LP $300.0003/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685146975 CMS
AstraZeneca Pharmaceuticals LP $4,100.0003/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685309039 CMS
Clovis Oncology, Inc. $3,500.0003/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688682275 CMS
TherapeuticsMD, Inc. $15.7503/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703043523 CMS
Clovis Oncology, Inc. $13.0603/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688688333 CMS
AstraZeneca Pharmaceuticals LP $749.6702/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685720635 CMS
AstraZeneca Pharmaceuticals LP $125.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685740023 CMS
AstraZeneca Pharmaceuticals LP $115.6502/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685138255 CMS
AstraZeneca Pharmaceuticals LP $1,356.9802/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685462323 CMS
AstraZeneca Pharmaceuticals LP $183.3402/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685894131 CMS
AstraZeneca Pharmaceuticals LP $83.8402/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685930905 CMS
Clovis Oncology, Inc. $357.4402/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688682277 CMS
Clovis Oncology, Inc. $140.7002/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688682281 CMS
Clovis Oncology, Inc. $136.8502/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688682273 CMS
Clovis Oncology, Inc. $124.9902/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688682279 CMS
Amgen Inc. $125.0002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662852413 CMS
AstraZeneca Pharmaceuticals LP $2,750.0002/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685039397 CMS
AstraZeneca Pharmaceuticals LP $4,800.0002/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685260877 CMS
AstraZeneca Pharmaceuticals LP $69.8802/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685259113 CMS
AstraZeneca Pharmaceuticals LP $118.3602/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685998987 CMS
AstraZeneca Pharmaceuticals LP $125.1602/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685248279 CMS
Kyowa Kirin, Inc. $18.9902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687560325 CMS
TESARO, Inc. $121.0102/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555703 CMS
AstraZeneca Pharmaceuticals LP $141.0201/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685492953 CMS
AstraZeneca Pharmaceuticals LP $11.1001/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685657541 CMS
AstraZeneca Pharmaceuticals LP $588.4501/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685886269 CMS
AstraZeneca Pharmaceuticals LP $70.4101/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685927735 CMS
AstraZeneca Pharmaceuticals LP $91.8401/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686009159 CMS
Clovis Oncology, Inc. $11.2401/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688685795 CMS
Merck Sharp & Dohme Corporation $16.2001/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695218619 CMS
TESARO, Inc. $101.2301/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555697 CMS
TESARO, Inc. $17.4001/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555699 CMS
TESARO, Inc. $2,400.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555701 CMS
TherapeuticsMD, Inc. $13.6501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703043521 CMS
AstraZeneca Pharmaceuticals LP $1,250.0001/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685692823 CMS
TESARO, Inc. $114.4201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555691 CMS
TESARO, Inc. $58.3601/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555693 CMS
TESARO, Inc. $2,400.0001/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675555695 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $57,423.65 100
PY2020 $22,162.46 26
PY2021 $29,810.18 31
PY2022 $13,315.99 32
PY2023 $3,775.29 32
PY2024 $2,969.01 22
PY2025 $1,024.61 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $256,878.73 120
PY2024 Principal investigator $175,189.36 90
PY2023 Principal investigator $378,270.07 60
PY2022 Principal investigator $1,211,985.36 47
PY2021 Principal investigator $1,133,830.88 42
PY2020 Principal investigator $1,294,445.94 83
PY2019 Recipient $12,480.00 5
PY2019 Principal investigator $1,408,927.51 87

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1,168.17 12/31/2025 Non-covered Recipient Entity
Women's Cancer Care
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926771
Principal investigator 1 Merck Sharp & Dohme LLC $3,579.81 12/31/2025 Non-covered Recipient Entity
Women's Cancer Care
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer KEYNOTE-A18 , ENGOT-cx11,GOG-3047 No dispute reported 06/30/2026 1232927291
Principal investigator 1 Merck Sharp & Dohme LLC $10,476.70 12/31/2025 Non-covered Recipient Entity
Women's Cancer Care
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 1232936704
Principal investigator 1 GlaxoSmithKline, LLC. $711.95 12/30/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183300
Principal investigator 1 GlaxoSmithKline, LLC. $6,562.56 12/24/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183245
Principal investigator 1 GlaxoSmithKline, LLC. $805.41 11/27/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183296
Principal investigator 1 GlaxoSmithKline, LLC. $1,821.21 11/12/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183232
Principal investigator 1 Merck Sharp & Dohme LLC $36,982.00 10/22/2025 Non-covered Recipient Entity
Women's Cancer Care
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926769
Principal investigator 1 GlaxoSmithKline, LLC. $7,003.10 09/24/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183254
Principal investigator 1 GlaxoSmithKline, LLC. $960.30 09/17/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192183229
Principal investigator 1 ABBVIE INC. $12,884.00 09/16/2025 Non-covered Recipient Entity
WOMEN S CANCER CARE
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202511114
Principal investigator 1 Organon Llc $18,775.00 09/11/2025 Non-covered Recipient Entity
Women's Cancer Care
3475-587 No dispute reported 06/30/2026 1173042172
Principal investigator 1 Organon Llc $625.00 09/11/2025 Non-covered Recipient Entity
Women's Cancer Care
3475-587 No dispute reported 06/30/2026 1173042238
Principal investigator 1 GlaxoSmithKline, LLC. $6,562.56 09/05/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183257
Principal investigator 1 GlaxoSmithKline, LLC. $7,598.70 08/28/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192183236
Principal investigator 1 ABBVIE INC. $35,000.00 08/14/2025 Non-covered Recipient Entity
WOMEN S CANCER CARE-
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer No dispute reported 06/30/2026 1202504947
Principal investigator 1 Merck Sharp & Dohme LLC $19,236.00 08/13/2025 Non-covered Recipient Entity
Women's Cancer Care
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 1232936702
Principal investigator 1 SpringWorks Therapeutics, Inc. $500.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169676
Principal investigator 1 SpringWorks Therapeutics, Inc. $750.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169680
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169684
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169687
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169691
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169696
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169701
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169704
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169707
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169711
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169715
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169720
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169724
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169729
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169733
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169737
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169741
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169745
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169749
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169753
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169758
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169762
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169766
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169770
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169774
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169778
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169782
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169785
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169790
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169795
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169798
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169803
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169806
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169810
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169815
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169818
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169821
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169825
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169828
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169834
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169837
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169842
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169846
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169850
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169853
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169856
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169860
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169863
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169868
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169872
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169876
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169879
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169883
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169887
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169891
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169895
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169898
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169901
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169905
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169908
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169912
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169917
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169921
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169924
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169929
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169932
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169936
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169941
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169944
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169948
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169952
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169956
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169959
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169964
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169968
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169972
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169975
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169979
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169983
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169988
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169992
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169996
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170000
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170003
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170008
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170013
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170016
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170020
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170024
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170029
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170033
Principal investigator 1 SpringWorks Therapeutics, Inc. $50.00 07/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232170036
Principal investigator 1 GlaxoSmithKline, LLC. $5,757.15 06/20/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183292
Principal investigator 1 SpringWorks Therapeutics, Inc. $250.00 06/17/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232169536
Principal investigator 1 ABBVIE INC. $38,200.00 06/04/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202490151
Principal investigator 1 GlaxoSmithKline, LLC. $4,146.33 06/02/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183250
Principal investigator 1 GlaxoSmithKline, LLC. $6,482.79 05/22/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183287
Principal investigator 1 ABBVIE INC. $6,181.20 05/09/2025 Non-covered Recipient Entity
PATRICIA BRALY MD APMC
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) No dispute reported 06/30/2026 1202484599
Principal investigator 1 GlaxoSmithKline, LLC. $12,319.71 05/02/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183240
Principal investigator 1 SpringWorks Therapeutics, Inc. $236.25 04/15/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232168605
Principal investigator 1 SpringWorks Therapeutics, Inc. $236.25 02/19/2025 Non-covered Recipient Entity
WOMEN'S CANCER CARE
NIR-OGT-201 No dispute reported 06/30/2026 1232168418
Principal investigator 1 GlaxoSmithKline, LLC. $2,878.58 02/14/2025 Non-covered Recipient Entity
WOMENS CANCER CARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192183283
Principal investigator 1 ABBVIE INC. $3,688.00 01/29/2025 Non-covered Recipient Entity
WOMEN S CANCER CARE
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202442991